Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Andrew David Norden, M.D.

TitleAssistant Professor of Neurology
InstitutionDana-Farber Cancer Institute
DepartmentNeurology
AddressDana Farber Cancer Institute
Center for Neuro-oncology, SW430
44 Binney St
Boston MA 02115
Phone617/632-2166
Fax617/632-4773

 Mentoring 
 completed student projects
Identifying Imaging & Molecular Predictors of Response to Bevacizumab in Recurrent Glioblastoma
Summer, 06/14/10 - 08/09/10

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Craig JM, Vena N, Ramkissoon S, Idbaih A, Fouse SD, Ozek M, Sav A, Hill DA, Margraf LR, Eberhart CG, Kieran MW, Norden AD, Wen PY, Loda M, Santagata S, Ligon KL, Ligon AH. DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. PLoS One. 2012; 7(6):e38881.
    View in: PubMed
  2. Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, Omuro A, Kaley TJ. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012 Aug; 109(1):187-93.
    View in: PubMed
  3. Drappatz J, Lee EQ, Hammond S, Grimm SA, Norden AD, Beroukhim R, Gerard M, Schiff D, Chi AS, Batchelor TT, Doherty LM, Ciampa AS, Lafrankie DC, Ruland S, Snodgrass SM, Raizer JJ, Wen PY. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma. J Neurooncol. 2012 Mar; 107(1):133-8.
    View in: PubMed
  4. Kesselheim JC, Norden AD, Wen PY, Joffe S. Discontinuing bevacizumab in patients with glioblastoma: an ethical analysis. Oncologist. 2011; 16(10):1435-9.
    View in: PubMed
  5. Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY, Friedman HS. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol. 2012 Jan; 106(2):409-15.
    View in: PubMed
  6. Norden AD, Bartolomeo J, Tanaka S, Drappatz J, Ciampa AS, Doherty LM, Lafrankie DC, Ruland S, Quant EC, Beroukhim R, Wen PY. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J Neurooncol. 2012 Jan; 106(1):121-5.
    View in: PubMed
  7. Lu-Emerson C, Norden AD, Drappatz J, Quant EC, Beroukhim R, Ciampa AS, Doherty LM, Lafrankie DC, Ruland S, Wen PY. Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure. J Neurooncol. 2011 Aug; 104(1):287-91.
    View in: PubMed
  8. Young GS, Macklin EA, Setayesh K, Lawson JD, Wen PY, Norden AD, Drappatz J, Kesari S. Longitudinal MRI evidence for decreased survival among periventricular glioblastoma. J Neurooncol. 2011 Aug; 104(1):261-9.
    View in: PubMed
  9. Sure D, Dunn I, Norden A, Anderson WS. Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide. Clin Neurol Neurosurg. 2010 Oct; 112(8):741-2.
    View in: PubMed
  10. Wen PY, Quant E, Drappatz J, Beroukhim R, Norden AD. Medical therapies for meningiomas. J Neurooncol. 2010 Sep; 99(3):365-78.
    View in: PubMed
  11. Quant EC, Drappatz J, Wen PY, Norden AD. Recurrent high-grade glioma. Curr Treat Options Neurol. 2010 Jul; 12(4):321-33.
    View in: PubMed
  12. Norden AD, Drappatz J, Wen PY, Claus EB. Survival among patients with primary central nervous system lymphoma, 1973-2004. J Neurooncol. 2011 Feb; 101(3):487-93.
    View in: PubMed
  13. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin. 2010 May-Jun; 60(3):166-93.
    View in: PubMed
  14. Drappatz J, Norden AD, Wong ET, Doherty LM, Lafrankie DC, Ciampa A, Kesari S, Sceppa C, Gerard M, Phan P, Schiff D, Batchelor TT, Ligon KL, Young G, Muzikansky A, Weiss SE, Wen PY. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2010 Sep 1; 78(1):85-90.
    View in: PubMed
  15. Wen PY, Norden AD, Drappatz J, Quant E. Response assessment challenges in clinical trials of gliomas. Curr Oncol Rep. 2010 Jan; 12(1):68-75.
    View in: PubMed
  16. Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol. 2009 Dec; 11(6):853-60.
    View in: PubMed
  17. Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol. 2009 Nov; 5(11):610-20.
    View in: PubMed
  18. Chi AS, Norden AD, Wen PY. Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics. 2009 Jul; 6(3):513-26.
    View in: PubMed
  19. Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010 Jan; 96(2):211-7.
    View in: PubMed
  20. Norden AD, Drappatz J, Wen PY. Advances in meningioma therapy. Curr Neurol Neurosci Rep. 2009 May; 9(3):231-40.
    View in: PubMed
  21. Drappatz J, Norden AD, Wen PY. Therapeutic strategies for inhibiting invasion in glioblastoma. Expert Rev Neurother. 2009 Apr; 9(4):519-34.
    View in: PubMed
  22. Quant EC, Norden AD, Drappatz J, Muzikansky A, Doherty L, Lafrankie D, Ciampa A, Kesari S, Wen PY. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol. 2009 Oct; 11(5):550-5.
    View in: PubMed
  23. Gerstner ER, McNamara MB, Norden AD, Lafrankie D, Wen PY. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol. 2009 Aug; 94(1):97-101.
    View in: PubMed
  24. Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, Muzikansky A, Santagata S, Ligon KL, Norden AD, Ciampa A, Bradshaw J, Levy B, Radakovic G, Ramakrishna N, Black PM, Wen PY. Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res. 2009 Jan 1; 15(1):330-7.
    View in: PubMed
  25. Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. 2008 Dec; 7(12):1152-60.
    View in: PubMed
  26. Dietrich J, Norden AD, Wen PY. Emerging antiangiogenic treatments for gliomas - efficacy and safety issues. Curr Opin Neurol. 2008 Dec; 21(6):736-44.
    View in: PubMed
  27. Norden AD, Drappatz J, Muzikansky A, David K, Gerard M, McNamara MB, Phan P, Ross A, Kesari S, Wen PY. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol. 2009 Apr; 92(2):149-55.
    View in: PubMed
  28. Norden AD, Drappatz J, Wen PY. Antiangiogenic therapy in malignant gliomas. Curr Opin Oncol. 2008 Nov; 20(6):652-61.
    View in: PubMed
  29. Bracht LK, Wen P, Meyerhardt JA, Kulke MH, Hornick JL, Redston M, LaFrankie DC, Black PM, Kesari S, Norden A, Drappatz J. DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor. J Clin Oncol. 2008 Oct 10; 26(29):4843-4.
    View in: PubMed
  30. Norden AD, Drappatz J, Ciampa AS, Doherty L, LaFrankie DC, Kesari S, Wen PY. Colon perforation during antiangiogenic therapy for malignant glioma. Neuro Oncol. 2009 Feb; 11(1):92-5.
    View in: PubMed
  31. Drappatz J, Wong ET, Schiff D, Kesari S, Batchelor TT, Doherty L, Lafrankie DC, Ramakrishna N, Weiss S, Smith ST, Ciampa A, Zimmerman J, Ostrowsky L, David K, Norden A, Barron L, Sceppa C, Black PM, Wen PY. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009 Jan 1; 73(1):222-7.
    View in: PubMed
  32. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008 Mar 4; 70(10):779-87.
    View in: PubMed
  33. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy BA, Drappatz J, Kesari S, Wen PY. Retrospective study of bevacizumab for malignant gliomas and analysis of the patterns of recurrence. American Academy of Neurology Abstract. 2008; 326.
  34. Norden A, Hochberg E, Hochberg FH. Secondary involvement of the central nervous system by non-Hodgkin's lymphoma. 2008.
  35. Norden AD, Wen PW. Chemotherapy and Experimental Medical Therapy for Meningiomas. Meningiomas: A Comprehensive Text (Pamir N, Fahlbusch R, Black PM, editors). 2008.
  36. Norden AD, Wen PY. Malignant Gliomas. Blue Books in Neurology Series: Neuro-Oncology. 2008.
  37. Norden AD, Wen PY. Inhibitors of Signal Transduction Pathways in Malignant Glioma Therapy. Principles and Practices of Neuro-Oncology: A Multidisciplinary Approach (Mehta M, Chang S, Vogelbaum K, Guha A, et al., editors). 2008.
  38. Norden AD, Kesari S. Pituitary adenoma. 2007.
  39. Drappatz J, Schiff D, Kesari S, Norden AD, Wen PY. Medical management of brain tumor patients. Neurol Clin. 2007 Nov; 25(4):1035-71, ix.
    View in: PubMed
  40. Chi A, Norden AD, Wen PY. Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev Anticancer Ther. 2007 Nov; 7(11):1537-60.
    View in: PubMed
  41. Norden AD, Batchelor TT. Reversible posterior leukoencephalopathy syndrome. Onkologie. 2007 Mar; 30(3):90-1.
    View in: PubMed
  42. Norden AD, Drappatz J, Wen PY. Targeted drug therapy for meningiomas. Neurosurg Focus. 2007; 23(4):E12.
    View in: PubMed
  43. Norden A, Hochberg E, Hochberg FH. Secondary involvement of the central nervous system by non-Hodgkin's lymphoma. 2007.
  44. Norden AD, Kesari S. Cancer neurology: primary CNS lymphoma, paraneoplastic syndromes, and pituitary adenoma. Hospital Physician Neurology Board Review Manual. Atri A, Millgan TA, editors. 2007; 11(1):1-16.
  45. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy BA, Drappatz J, Kesari S, Wen PY. Retrospective study of bevacizumab for malignant gliomas and analysis of the patterns of recurrence. Society for Neuro-Oncology Abstract. Neuro-Oncology. 2007; 9(4):515-516.
  46. Norden AD, Kesari S. Pituitary adenoma. 2006.
  47. Norden AD, Wen PY. Glioma therapy in adults. Neurologist. 2006 Nov; 12(6):279-92.
    View in: PubMed
  48. Norden AD, Kesari S. Cancer neurology: primary and metastatic brain tumors. Hospital Physician Neurology Board Review Manual. Atri A, Millgan TA, editors. 2006; 10(3):1-16.
  49. Norden A, Hochberg E, Hochberg FH. Secondary involvement of the central nervous system by non-Hodgkin's lymphoma. 2006.
  50. Norden AD, Wen PY, Kesari S. Brain metastases. Curr Opin Neurol. 2005 Dec; 18(6):654-61.
    View in: PubMed
  51. Blumenfeld H, McNally KA, Vanderhill SD, Paige AL, Chung R, Davis K, Norden AD, Stokking R, Studholme C, Novotny EJ, Zubal IG, Spencer SS. Positive and negative network correlations in temporal lobe epilepsy. Cereb Cortex. 2004 Aug; 14(8):892-902.
    View in: PubMed
  52. Norden AD, Blumenfeld H. The role of subcortical structures in human epilepsy. Epilepsy Behav. 2002 Jun; 3(3):219-231.
    View in: PubMed
  53. Norden AD, Levy S, Testa F, Novotny EJ. A novel epilepsy syndrome secondary to neonatal hypoglycemia. American Epilepsy Society Abstract. Epilepsia. 2001; 42(S7):50 (1.154).
  54. Blumenfeld H, Norden A, Studholme C, Zubal G, Spencer S. Bilateral thalamic and brainstem involvement in seizures revealed by SPECT ictal-interictal difference imaging. American Academy of Neurology Abstract. Neurology. 2000; 54(7-S3):S02.002.
  55. Paige L, Bradley C, Chang D, Studholme C, Stokking R, Norden A, Zubal IG, Spencer SS, Blumenfeld H. SPECT ictal-interictal difference imaging reveals thalamic and brainstem reticular formation involvement in seizures. American Epilepsy Society Abstract. Epilepsia. 2000; 41(S7):68 (1.243).
  56. Bradley C, Paige L, Chang D, Studholme C, Stokking R, Norden A, Zubal IG, Spencer SS, Blumenfeld H. Thalamic and pontomesencephalic reticular formation involvement in seizures studied by SPECT ictal-interictal difference imaging. Society for Neuroscience Abstract. 2000; 26:1010 (376.1).
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Norden's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (153) concept(s)
_
Co-Authors
See all (28) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_